Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: Improved completion rates but more hepatotoxicity

Chest

Volumn 123, Issue 1, 2003, Pages 102-106

  McNeill, Lee ^a,b   Allen, Myra ^a   Estrada, Carlos ^a   Cook, Paul ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b PITT COUNTY MEMORIAL HOSPITAL   (United States)

Author keywords

Antitubercular agents; Hepatitis; Patient compliance; Pulmonary; Tuberculin test; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037245531     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.1.102     Document Type: Article

References (11)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-S247
2. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid vs rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786-792
3. Gordin F, Chaisson RE, Matts JP, et al. Rifampin, and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000; 283:1445-1450
4. Centers for Disease Control and Prevention. Use of short-course tuberculosis preventative therapy regimens in HIV-seronegative persons. MMWR Morb Mortal Wkly Rep 1998; 47:911-912
5. Centers for Disease Control. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:289-291
6. Centers for Disease Control update. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revision in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733-735
7. Geiter LJ, O'Brien RJ, Kopanoff DE. Short-course preventive therapy for tuberculosis [abstract]. Am J Respir Crit Care Med 1990; 141(Pt 2):A437
8. Geiter LJ. Results of a randomized, controlled trial to assess the toxicity and patient adherence with two short-course regimens for the prevention of tuberculosis, a two-month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six months-isoniazide [thesis]. Baltimore, MD: Johns Hopkins University, School of Hygiene and Public Health,
9. Bock NN, Rogers T, Tapia JR, et al. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 2001; 119:833-835
10. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112:397-406
11. Magdorf K, Arizzi-Ruche AF, Geiter LJ, et al. Compliance and tolerance of new antituberculotic short-term chemoprevention regimes in childhood: a pilot study. Pneumologie 1994; 48:761-764